共 352 条
[1]
Gershenwald JE(2017)Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual CA Cancer J Clin 67 472-492
[2]
Scolyer RA(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34
[3]
Hess KR(2010)Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases J Clin Oncol 28 2452-2459
[4]
Siegel RL(1996)Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 Journal of clinical oncology : official journal of the American Society of Clinical Oncology 14 7-17
[5]
Miller KD(2010)Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 102 493-501
[6]
Jemal A(2004)A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma Clin Cancer Res 10 1670-1677
[7]
Balch CM(2000)High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2444-2458
[8]
Gershenwald JE(2009)Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma J Clin Oncol 27 939-944
[9]
Soong SJ(2012)Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma J Clin Oncol 30 3810-3818
[10]
Thompson JF(2012)Melanoma J Natl Compr Cancer Netw 10 366-400